Bioanalysis of new designer drugs

Bioanalysis

Volumn 2, Issue 5, 2010, Pages 965-979

  Wohlfarth, Ariane ^a   Weinmann, Wolfgang ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIMETHOXY METHYLTHIOAMPHETAMINE; 4 METHOXYAMPHETAMINE; AMPHETAMINE DERIVATIVE; CANNABINOID; DESIGNER DRUG; DIFURANYLPHENALKYLAMINE DERIVATIVE; MESCALINE; PHENCYCLIDINE DERIVATIVE; PHENYLALKYLAMINE; PHENYLCYCLOHEXYL DERIVATIVE; PIPERAZINE DERIVATIVE; PSYCHEDELIC AGENT; PYRROLIDINE DERIVATIVE; PYRROLIDINOPHENONE DERIVATIVE; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; CONCENTRATION (PARAMETERS); DRUG CLASSIFICATION; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; REVIEW; SCREENING TEST; SOLID PHASE EXTRACTION; CHEMICAL ANALYSIS; CLASSIFICATION; HUMAN; METHODOLOGY; STANDARD; SUBSTANCE ABUSE;

CHEMISTRY TECHNIQUES, ANALYTICAL; DESIGNER DRUGS; HUMANS; IMMUNOASSAY; REFERENCE STANDARDS; SUBSTANCE ABUSE DETECTION;

EID: 77956650046     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.32     Document Type: Review

References (122)

1. Campbell H, Cline W, Evans M, Lloyd J, Peck AW. Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur. J. Clin. Pharmacol. 6, 170-176 (1973).
2. Howlett AC, Barth F, Bonner TI et al. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54(2), 161-202 (2002). (Pubitemid 34575709)
3. United Nations Office on Drugs and Crime. World Drug Report 2008. United Nations Publication, NY, USA (2009).
4. Shulgin AT, Shulgin A. PIHKAL: A Chemical Love Story. Transform Press, CA, USA (1991).
5. Shulgin AT, Shulgin A. TIHKAL: The Continuation. Transform Press, CA, USA (1997).
6. De Boer D, Egberts T, Maes RA. Para-methylthioamphetamine, a new amphetamine designer drug of abuse. Pharm. World Sci. 21(1), 47-48 (1999). (Pubitemid 29161700)
7. Felgate HE, Felgate PD, James RA, Sims DN, Vozzo DC. Recent paramethoxyamphetamine deaths. J. Anal. Toxicol. 22(2), 169-172 (1998). (Pubitemid 28128966)
8. James RA, Dinan A. Hyperpyrexia associated with fatal paramethoxyamphetamine (PMA) abuse. Med. Sci. Law 38(1), 83-85 (1998). (Pubitemid 128456964)
9. Ling LH, Marchant C, Buckley NA, Prior M, Irvine RJ. Poisoning with the recreational drug paramethoxyamphetamine ('death').Med. J. Aust. 174(9), 453-455 (2001). (Pubitemid 32466069)
10. Kraner JC, McCoy DJ, Evans MA, Evans LE, Sweeney BJ. Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA).J. Anal. Toxicol. 25(7), 645-648 (2001). (Pubitemid 32939075)
11. Casale JF, Hays PA, Spratley TK, Smith PR. The characterization of 4-methoxy-n-ethylamphetamine hydrochloride. Microgram J. 4, 42-45 (2006).
12. Zaitsu K, Katagi M, Kamata T et al. Determination of a newly encountered designer drug 'p-methoxyethylamphetamine' and its metabolites in human urine and blood. Forensic Sci. Int. 177(1), 77-84 (2008).
13. Boatto G, Nieddu M, Dessi G, Manconi P, Cerri R. Determination of four thiophenethylamine designer drugs (2C-T-series) in human plasma by capillary electrophoresis with mass spectrometry detection. J. Chromatogr. A 1159(1-2), 198-202 (2007). (Pubitemid 47048237)
14. Boatto G, Nieddu M, Pirisi MA, Dessi G. Simultaneous determination of new thioamphetamine designer drugs in plasma by capillary electrophoresis coupled with mass spectrometry. Rapid Commun. Mass Spectrom. 21(22), 3716-3720 (2007). (Pubitemid 350124642)
15. Habrdova V, Peters FT, Theobald DS, Maurer HH. Screening for and validated quantification of phenethylamine-type designer drugs and mescaline in human blood plasma by gas chromatography/mass spectrometry. J. Mass Spectrom. 40(6), 785-795 (2005). (Pubitemid 40905244)
16. Bossong MG, Van Dijk JP, Niesink RJ. Methylone and MCPP, two new drugs of abuse? Addict. Biol. 10(4), 321-323 (2005). (Pubitemid 41759265)
17. Kamata HT, Shima N, Zaitsu K et al. Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica 36(8), 709-723 (2006). (Pubitemid 44195985)
18. Zaitsu K, Katagi M, Kamata H, Miki A, Tsuchihashi H. Discrimination and identification of regioisomeric b-keto analogues of 3,4- methylendioxyamphetamines by gas chromatography-mass spectrometry. Forensic Toxicol. 26, 45-51 (2008).
19. Zaitsu K, Katagi M, Kamata HT et al. Determination of the metabolites of the new designer drugs BK-MBDB and BK-MDEA in human urine. Forensic Sci. Int. 188(1-3), 131-139 (2009).
20. Rosner P, Quednow B, Girreser U, Junge T. Isomeric fluoro-methoxy- phenylalkylamines: a new series of controlled-substance analogues (designer drugs).Forensic Sci. Int. 148(2-3), 143-156 (2005). (Pubitemid 40082404)
21. Carmo H, Brulport M, Hermes M et al. Cyp2d6 increases toxicity of the designer drug 4-methylthioamphetamine (4-MTA).Toxicology 229(3), 236-244 (2007). (Pubitemid 44937495)
22. Elliott SP. Fatal poisoning with a new phenylethylamine: 4-methylthioamphetamine (4-MTA).J. Anal. Toxicol. 24(2), 85-89 (2000). (Pubitemid 30134309)
23. Blachut D, Wojtasiewicz K, Czarnocki Z, Szukalski B. The analytical profile of some 4-methylthioamphetamine (4-MTA) homologues. Forensic Sci. Int. 192(1-3), 98-114 (2009).
24. Puchnarewicz M, Davies S, Button J et al. Bromodragonfly - gives you wings? Ann. Toxicol. Anal. 21(S1), 57 (2009).
25. Wood Dm, Looker J, Shaikh L et al. Delayed onset of seizures and toxicity associated with recreational use of bromo-dragonfly. J. Med. Toxicol. 5(4), 226-229 (2009).
26. Alatrash G, Majhail NS, Pile JC. Rhabdomyolysis after ingestion of 'foxy' a hallucinogenic tryptamine derivative. Mayo Clin. Proc. 81(4), 550-551 (2006).
27. Meatherall R, Sharma P. Foxy, a designer tryptamine hallucinogen. J. Anal. Toxicol. 27(5), 313-317 (2003).
28. Tanaka E, Kamata T, Katagi M, Tsuchihashi H, Honda K. A fatal poisoning with 5-methoxy- N,N-diisopropyltryptamine, foxy. Forensic Sci. Int. 163(1-2), 152-154 (2006). (Pubitemid 44442804)
29. Wilson JM, McGeorge F, Smolinske S, Meatherall R. A foxy intoxication. Forensic Sci. Int. 148(1), 31-36 (2005). (Pubitemid 40029393)
30. De Boer D, Bosman IJ, Hidvegi E et al. Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci. Int. 121(1-2), 47-56 (2001). (Pubitemid 32758813)
31. Drug Enforcement Administration (DEA), Department of Justice. Schedules of controlled substances: placement of a-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the controlled substances act. Final rule. Fed. Regist. 69(188), 58950-58953 (2004).
32. Staack RF, Maurer HH. New designer drug 1-(3,4-methylenedioxybenzyl) piperazine (MDBP): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom. 39(3), 255-261 (2004). (Pubitemid 38372420)
33. Staack RF, Maurer HH. Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (MCPP): GC-MS studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nefazodone. J. Anal. Toxicol. 27(8), 560-568 (2003). (Pubitemid 37500377)
34. Staack RF, Maurer HH. Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 798(2), 333-342 (2003). (Pubitemid 37487734)
35. Westphal F, Junge T, Girreser U, Stobbe S, Perez SB. Structure elucidation of a new designer benzylpiperazine: 4-bromo-2,5- dimethoxybenzylpiperazine. Forensic Sci. Int. 187(1-3), 87-96 (2009).
36. Maurer HH, Kraemer T, Springer D, Staack RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther. Drug Monit. 26(2), 127-131 (2004). (Pubitemid 38501205)
37. Sauer C, Peters FT, Haas C, Meyer MR, Fritschi G, Maurer HH. New designer drug a-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 44(6), 952-964 (2009).
38. Sauer C, Peters FT, Staack RF, Fritschi G, Maurer HH. New designer drug n-(1- phenylcyclohexyl)-3-ethoxypropanamine (PCEPA): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 41(8), 1014-1029 (2006). (Pubitemid 44338553)
39. EMCDDA-Europol 2008 Annual Report on the Implementation of Council Decision 2005/387/JHA. Annex 2: new psychoactive substances reported to the EMCDDA and Europol for the first time in 2008 under the terms of council decision 2005/387/jha. Council of the European Union, Brussels, 20-21 (2009).
40. Lidder S, Dargan P, Sexton M et al. Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl- 2-pyrrolidinemethanol [D2PM]).J. Med. Toxicol. 4(3), 167-169 (2008).
41. Wood D. Detection of the novel recreational drug diphenyl-2- pyrrolidinemethanol (D2PM) sold legally in combination with 1-benzylpiperzaine (BZP).Clin. Tox. 46, 393 (2008).
42. NIST/EPA/NIH Mass Spectral Library. Scientific instrument services, Inc., NJ, USA (2008).
43. Maurer HH, Pfleger K, Weber AA. Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites. Wiley, Altenholz, Germany (2007).
44. McLafferty FW. Wiley Registry of Mass Spectral Data (9th Edition).Wiley, Altenholz, Germany (2009).
45. Mass Spectrometry Databse Committee. 'Comprehensive' Drug Mass Spectral Library. University of Alberta, Alberta, Canada (2009).
46. Rosner P, Junge T, Westphal F, Fritschi G. Mass Spectra of Designer Drugs: Including Drugs, Chemical Warfare Agents, and Precursors. Wiley, Altenholz, Germany (2007).
47. Laks S, Pelander A, Vuori E, Ali-Tolppa E, Sippola E, Ojanpera I. Analysis of street drugs in seized material without primary reference standards. Anal. Chem. 76(24), 7375-7379 (2004). (Pubitemid 39658010)
48. Ojanpera S, Pelander A, Pelzing M, Krebs I, Vuori E, Ojanpera I. Isotopic pattern and accurate mass determination in urine drug screening by liquid chromatography/ time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 20(7), 1161-1167 (2006).
49. Pelander A, Tyrkko E, Ojanpera I. In silico methods for predicting metabolism and mass fragmentation applied to quetiapine in liquid chromatography/time-of-flight mass spectrometry urine drug screening. Rapid Commun. Mass Spectrom. 23(4), 506-514 (2009).
50. Ferreiros Bouzas N, Dresen S, Munz B, Weinmann W. Determination of basic drugs of abuse in human serum by online extraction and LC-MS/MS. Anal. Bioanal. Chem. 395(8), 2499-507 (2009).
51. Boland DM, Andollo W, Hime GW, Hearn WL. Fatality due to acute a-methyltryptamine intoxication. J. Anal. Toxicol. 29(5), 394-397 (2005). (Pubitemid 41191711)
52. Vorce SP, Holler JM, Levine B, Past MR. Detection of 1-benzylpiperazine and 1-(3-trifluoromethylphenyl)-piperazine in urine analysis specimens using GC-MS and LC-ESI-MS. J. Anal. Toxicol. 32(6), 444-450 (2008).
53. Miyajima M, Matsumoto T, Ito S. 2C-T-4 intoxication: acute psychosis caused by a designer drug. Psychiatry Clin. Neurosci. 62(2), 243 (2008). (Pubitemid 351537718)
54. Cody JT, Schwarzhoff R. Fluorescence polarization immunoassay detection of amphetamine, methamphetamine, and illicit amphetamine analogues. J. Anal. Toxicol. 17(1), 23-33 (1993).
55. Ishida T, Kudo K, Inoue H, Tsuji A, Kojima T, Ikeda N. Rapid screening for and simultaneous semiquantitative analysis of thirty abused drugs in human urine samples using gas chromatography-mass spectrometry. J. Anal. Toxicol. 30(7), 468-477 (2006). (Pubitemid 44371490)
56. Nordgren HK, Beck O. Multicomponent screening for drugs of abuse: direct analysis of urine by LC-MS/MS. Ther. Drug Monit. 26(1), 90-97 (2004). (Pubitemid 38140917)
57. Peters FT, Schaefer S, Staack RF, Kraemer T, Maurer HH. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. J. Mass Spectrom. 38(6), 659-676 (2003). (Pubitemid 36818224)
58. Pichini S, Pujadas M, Marchei E et al. Liquid chromatography-atmospheric pressure ionization electrospray mass spectrometry determination of 'hallucinogenic designer drugs' in urine of consumers. J. Pharm. Biomed. Anal. 47(2), 335-342 (2008).
59. Vorce SP, Sklerov JH. A general screening and confirmation approach to the analysis of designer tryptamines and phenethylamines in blood and urine using GC-EI-MS and HPLC-electrospray-MS. J. Anal. Toxicol. 28(6), 407-410 (2004). (Pubitemid 39150357)
60. Wohlfarth A, Weinmann W, Dresen S. LC-MS/MS screening method for designer amphetamines, tryptamines and piperazines in serum. Anal. Bioanal. Chem. (2010) (Epub ahead of print).
61. Boatto G, Nieddu M, Carta A et al. Determination of amphetamine-derived designer drugs in human urine by SPE extraction and capillary electrophoresis with mass spectrometry detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 814(1), 93-98 (2005). (Pubitemid 40017940)
62. Nieddu M, Boatto G, Dessi G. Determination of 4-alkyl 2,5 dimethoxy-amphetamine derivatives by capillary electrophoresis with mass spectrometry detection from urine samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852(1-2), 578-581 (2007). (Pubitemid 46830159)
63. Nieddu M, Boatto G, Carta A, Sanna A, Pisano M. Simultaneous determination of ten amphetamine designer drugs in human whole blood by capillary electrophoresis with diode array detection. Biomed. Chromatogr. 19(10), 737-742 (2005). (Pubitemid 43013613)
64. Nieddu M, Boatto G, Pirisi Ma, Azara E, Marchetti M. LC-MS analysis of trimethoxyamphetamine designer drugs (TMA series) from urine samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 867(1), 126-130 (2008).
65. Carmo H, De Boer D, Remiao F, Carvalho F, Dos Reys LA, De Lourdes Bastos M. Metabolism of the designer drug 4-bromo- 2,5-dimethoxyphenethylamine (2C-B) in mice, after acute administration. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 811(2), 143-152 (2004). (Pubitemid 39451810)
66. Theobald DS, Fritschi G, Maurer HH. Studies on the toxicological detection of the designer drug 4-bromo-2,5-dimethoxy-b-phenethylamine (2C-B) in rat urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 846(1-2), 374-377 (2007). (Pubitemid 46149509)
67. De Boer D, Bosman I. A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs. Pharm. World Sci. 26(2), 110-113 (2004). (Pubitemid 38418600)
68. Takahashi M, Nagashima M, Suzuki J, Seto T, Yasuda I, Yoshida T. Analysis of phenylethylamines and tryptamines in designer drugs using gas chromatography- mass spectrometry. J. Health Sci. 54(1), 89-96 (2007).
69. Kanai K, Takekawa K, Kumamoto T, Ishikawa T, Ohmori T. Simultaneous analysis of six phenethylamine-type designer drugs by TLC, LC-MS, and GC-MS. Forensic Toxicol. 26, 6-12 (2008).
70. Nordgren HK, Holmgren P, Liljeberg P, Eriksson N, Beck O. Application of direct urine LC-MS-MS analysis for screening of novel substances in drug abusers. J. Anal. Toxicol. 29(4), 234-239 (2005). (Pubitemid 40827569)
71. Theobald DS, Maurer HH. Studies on the metabolism and toxicological detection of the designer drug 2,5-dimethoxy-4- methyl-b- phenethylamine (2C-D) in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 41(11), 1509-1519 (2006). (Pubitemid 44875661)
72. Theobald DS, Maurer HH. Studies on the metabolism and toxicological detection of the designer drug 4-ethyl-2,5-dimethoxy-b-phenethylamine (2C-E) in rat urine using gas chromatographic-mass spectrometric techniques. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 842(2), 76-90 (2006). (Pubitemid 44416629)
73. Theobald DS, Maurer HH. Identification of monoamine oxidase and cytochrome p450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series).Biochem. Pharmacol. 73(2), 287-297 (2007). (Pubitemid 44855724)
74. Theobald DS, Putz M, Schneider E, Maurer HH. New designer drug 4-iodo-2,5- dimethoxy-b-phenethylamine (2c-i): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric and capillary electrophoretic/mass spectrometric techniques. J. Mass Spectrom. 41(7), 872-886 (2006). (Pubitemid 44106048)
75. Nieddu M, Boatto G, Pirisi MA, Baralla E. Multi-residue analysis of eight thioamphetamine designer drugs in human urine by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 23(19), 3051-3056 (2009).
76. Theobald DS, Staack RF, Puetz M, Maurer HH. New designer drug 2,5-dimethoxy-4-ethylthio-b-phenethylamine (2C-T-2): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom. 40(9), 1157-1172 (2005). (Pubitemid 41337244)
77. Theobald DS, Fehn S, Maurer HH. New designer drug, 2,5-dimethoxy-4- propylthio-b-phenethylamine (2C-T-7): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J. Mass Spectrom. 40(1), 105-116 (2005). (Pubitemid 40188987)
78. Curtis B, Kemp P, Harty L, Choi C, Christensen D. Postmortem identification and quantitation of 2,5-dimethoxy-4-N-propylthiophenethylamine using GC-MSD and GC-NPD. J. Anal. Toxicol. 27(7), 493-498 (2003). (Pubitemid 37185861)
79. Ewald AH, Peters FT, Weise M, Maurer HH. Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 824(1-2), 123-131 (2005). (Pubitemid 41215589)
80. Uchiyama N, Kikura-Hanajiri R, Kawahara N, Goda Y. [Analysis of designer drugs detected in the products purchased in fiscal year 2006]. Yakugaku Zasshi 128(10), 1499-1505 (2008).
81. Archer RP. Fluoromethcathinone, a new substance of abuse. Forensic Sci. Int. 185(1-3), 10-20 (2009).
82. Kamata H, Shima N, Zaitsu K et al. Simultaneous analysis of new designer drug, methylone, and its metabolites in urine by gas chromatography-mass spectrometry and liquid chromatography- electrospray ionization mass spectrometry. Jpn J. Forensic Science Technol. 12(1), 97-106 (2007).
83. Shimizu E, Watanabe H, Kojima T et al. Combined intoxication with methylone and 5-MEO-MIPT. Prog. Neuropsychopharmacol. Biol. Psychiatry 31(1), 288-291 (2007). (Pubitemid 44959240)
84. Ewald AH, Fritschi G, Bork WR, Maurer HH. Designer drugs 2,5-dimethoxy- 4-bromo-amphetamine (DOB) and 2,5-dimethoxy-4-bromo-methamphetamine (MDOB): studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 41(4), 487-498 (2006). (Pubitemid 43668077)
85. Balikova M. Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetamine) overdose. Forensic Sci. Int. 153(1), 85-91 (2005). (Pubitemid 41008658)
86. Ewald AH, Ehlers D, Maurer HH. Metabolism and toxicological detection of the designer drug 4-chloro-2,5-dimethoxyamphetamine in rat urine using gas chromatography-mass spectrometry. Anal. BioAnal. Chem. 390(7), 1837-1842 (2008).
87. Ovaska H, Viljoen A, Puchnarewicz M et al. First case report of recreational use of 2,5-dimethoxy-4-chloroamphetamine confirmed by toxicolgical screening. Eur. J. Emerg. Med. 15, 354-356 (2008).
88. Ewald AH, Fritschi G, Maurer HH. Metabolism and toxicological detection of the designer drug 4-iodo-2,5-dimethoxy-amphetamine (DOI) in rat urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 857(1), 170-174 (2007). (Pubitemid 47362858)
89. Staack RF, Fehn J, Maurer HH. New designer drug p-methoxymethamphetamine: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 789(1), 27-41 (2003). (Pubitemid 36513784)
90. Mortier KA, Dams R, Lambert WE, De Letter EA, Van Calenbergh S, De Leenheer AP. Determination of paramethoxyamphetamine and other amphetamine-related designer drugs by liquid chromatography/sonic spray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 16(9), 865-870 (2002). (Pubitemid 34456287)
91. Zaitsu K, Katagi M, Kamata H et al. Discrimination and identification of the six aromatic positional isomers of trimethoxyamphetamine (TMA) by gas chromatography-mass spectrometry (GC-MS).J. Mass Spectrom. 43(4), 528-534 (2008). (Pubitemid 351518674)
92. Ewald AH, Fritschi G, Maurer HH. Designer drug 2,4,5- trimethoxyamphetamine (TMA-2): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 41(9), 1140-1148 (2006). (Pubitemid 44454167)
93. Sauer C, Peters FT, Staack RF, Fritschi G, Maurer HH. New designer drugs N-(1- phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and N-(1-phenylcyclohexyl)-2- methoxyethanamine (PCMEA): studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 43(3), 305-316 (2008). (Pubitemid 351373931)
94. Sauer C, Peters FT, Staack RF, Fritschi G, Maurer HH. Metabolism and toxicological detection of the designer drug N-(1- phenylcyclohexyl)-3- methoxypropanamine (PCMPA) in rat urine using gas chromatography-mass spectrometry. Forensic Sci. Int. 181(1), 47-51 (2008).
95. Sauer C, Peters FT, Staack RF, Fritschi G, Maurer HH. Metabolism and toxicological detection of a new designer drug, N-(1- phenylcyclohexyl) propanamine, in rat urine using gas chromatography-mass spectrometry. J. Chromatogr. A 1186(1-2), 380-390 (2008). (Pubitemid 351375218)
96. Staack RF, Fritschi G, Maurer HH. Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 773(1), 35-46 (2002). (Pubitemid 34518268)
97. Tsutsumi H, Katagi M, Miki A et al. Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 819(2), 315-322 (2005). (Pubitemid 40521967)
98. Tsutsumi H, Katagi M, Miki A et al. Metabolism and the urinary excretion profile of the recently scheduled designer drug N-benzylpiperazine (BZP) in the rat. J. Anal. Toxicol. 30(1), 38-43 (2006). (Pubitemid 44270341)
99. Wikstrom M, Holmgren P, Ahlner J. A2 (N-benzylpiperazine) a new drug of abuse in Sweden. J. Anal. Toxicol. 28(1), 67-70 (2004). (Pubitemid 38112321)
100. Elliott S, Smith C. Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J. Anal. Toxicol. 32(2), 172-177 (2008). (Pubitemid 351362752)
101. Wood DM, Dargan PI, Button J et al. Collapse, reported seizure - and an unexpected pill. Lancet 369(9571), 1490 (2007). (Pubitemid 46635785)
102. Bishop SC, McCord BR, Gratz SR, Loeliger JR, Witkowski MR. Simultaneous separation of different types of amphetamine and piperazine designer drugs by capillary electrophoresis with a chiral selector. J. Forensic Sci. 50(2), 326-335 (2005). (Pubitemid 40344257)
103. Staack RF, Paul LD, Schmid D, Roider G, Rolf B. Proof of a 1-(3-chlorophenyl) piperazine (MCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions? J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 855(2), 127-133 (2007). (Pubitemid 47212019)
104. Kovaleva J, Devuyst E, De Paepe P, Verstraete A. Acute chlorophenylpiperazine overdose: a case report and review of the literature. Ther. Drug Monit. 30(3), 394-398 (2008).
105. Staack RF, Fritschi G, Maurer HH. New designer drug 1-(3- trifluoromethylphenyl) piperazine (TFMPP): gas chromatography/ mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine. J. Mass Spectrom. 38(9), 971-981 (2003). (Pubitemid 37121814)
106. Tsutsumi H, Katagi M, Miki A et al. Isolation, identification and excretion profile of the principal urinary metabolite of the recently banned designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP) in rats. Xenobiotica 35(1), 107-116 (2005). (Pubitemid 40459221)
107. Springer D, Fritschi G, Maurer HH. Metabolism and toxicological detection of the new designer drug 3́,4́-methylenedioxy-a- pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 793(2), 377-388 (2003). (Pubitemid 37271978)
108. Springer D, Fritschi G, Maurer HH. Metabolism and toxicological detection of the new designer drug 4́-methoxy-a-pyrrolidinopropiophenone studied in rat urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 793(2), 331-342 (2003). (Pubitemid 37271973)
109. Peters FT, Meyer MR, Fritschi G, Maurer HH. Studies on the metabolism and toxicological detection of the new designer drug 4́-methyl-a- pyrrolidinobutyrophenone (MPBP) in rat urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 824(1-2), 81-91 (2005). (Pubitemid 41215584)
110. Westphal F, Junge T, Rosner P, Fritschi G, Klein B, Girreser U. Mass spectral and NMR spectral data of two new designer drugs with an a-aminophenone structure: 4́-methyl-a-pyrrolidinohexanophenone and 4́-methyl-a- pyrrolidinobutyrophenone. Forensic Sci. Int. 169(1), 32-42 (2007). (Pubitemid 46711226)
111. Springer D, Peters FT, Fritschi G, Maurer HH. New designer drug 4́-methyl-a-pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 789(1), 79-91 (2003). (Pubitemid 36513789)
112. Springer D, Paul LD, Staack RF, Kraemer T, Maurer HH. Identification of cytochrome p450 enzymes involved in the metabolism of 4́-methyl-a- pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes. Drug Metab. Dispos. 31(8), 979-982 (2003). (Pubitemid 36975667)
113. Springer D, Fritschi G, Maurer HH. Metabolism of the new designer drug a-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4́-methyl-a-pyrrolidinopropiophenone (mPPP) studied in rat urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 796(2), 253-266 (2003). (Pubitemid 37329670)
114. Westphal F, Junge T, Rosner P, Sonnichsen F, Schuster F. Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: a designer drug with a-pyrrolidinophenone structure. Forensic Sci. Int. 190(1-3), 1-8 (2009).
115. Spratley TK, Hays PA, Geer LC, Cooper SD, McKibben TD. Analytical profiles of five 'designer' tryptamines. Microgram J. 3, 54-68 (2005).
116. Chen BH, Liu JT, Chen WX, Chen HM, Lin CH. A general approach to the screening and confirmation of tryptamines and phenethylamines by mass spectral fragmentation. Talanta 74(4), 512-517 (2008).
117. Kamata T, Katagi M, Kamata HT et al. Metabolism of the psychotomimetic tryptamine derivative 5-methoxy-N,N-diisopropyltryptamine in humans: identification and quantification of its urinary metabolites. Drug Metab. Dispos. 34(2), 281-287 (2006). (Pubitemid 43145029)
118. Sklerov J, Levine B, Moore KA, King T, Fowler D. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J. Anal. Toxicol. 29(8), 838-841 (2005). (Pubitemid 41803388)
119. Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J. Mass Spectrom. 44(5), 832-837 (2009).
120. Lindigkeit R, Boehme A, Eiserloh I et al. Spice: a never ending story? Forensic Sci. Int. 191(1-3), 58-63 (2009).
121. Action on New Drugs Briefing Paper: Understanding The "Spice"Phenomenon. Presented at: EMCDDA Expert Meeting. Lisbon, Portugal, 6 March, 2009.
122. "Spice"- Plant Material(S) Laced with Synthetic Cannabinoids or Cannabinoid Mimicking Compounds. Drug Enforcement Administration Office of Forensic Sciences, DC, USA, 2009.